Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
5.7 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.25 | 0.263 | 0.259 | 0.264 | 0.056 |
| Gross Profit
| -0.25 | -0.263 | -0.259 | -0.264 | -0.056 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 48.225 | 29.459 | 47.306 | 44.937 | 24.681 |
| General & Administrative Expenses
| 11.892 | 13.335 | 15.374 | 11.283 | 9.985 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.892 | 13.335 | 15.374 | 11.283 | 9.985 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0.001 |
| Operating Expenses
| 60.117 | 42.794 | 62.68 | 56.22 | 34.667 |
| Operating Income
| -60.117 | -42.794 | -62.68 | -56.22 | -36.421 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.266 | 5.252 | 0.655 | -1.557 | -1.612 |
| Income Before Tax
| -55.851 | -37.543 | -62.025 | -57.776 | -38.033 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | -0.479 |
| Net Income
| -55.851 | -37.543 | -62.025 | -57.776 | -37.554 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.94 | -0.64 | -1.06 | -1.07 | -1.11 |
| EPS Diluted
| -0.94 | -0.64 | -1.06 | -1.07 | -1.11 |
| EBITDA
| -53.676 | -35.208 | -60.072 | -55.77 | -36.073 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |